Health-related quality-of-life in people living with HIV after switching to dual therapy with ritonavir-boosted darunavir + dolutegravir: a DUALIS sub-study

References

• Aboud, M., Orkin, C., Podzamczer, D., Bogner, J. R., Baker, D., Khuong-Josses, M. A., Parks, D., Angelis, K., Kahl, L. P., Blair, E. A., Adkison, K., Underwood, M., Matthews, J. E., Wynne, B., Vandermeulen, K., Gartland, M., & Smith, K. (2019). Efficacy and safety of dolutegravir–rilpivirine for maintenance of virological suppression in adults with HIV-1: 100-week data from the andomized, open-label, phase 3 SWORD-1 and SWORD-2 studies. The Lancet. HIV, 6(9), e576–e587. https://doi.org/https://doi.org/10.1016/S2352-3018(19)30149-3
   PubMed Web of Science ®Google Scholar
• Bates, D., Maechler, M., & Bolker, B. (2015). Walker., S. Fitting linear mixed-effects models using lme4. Journal of Statistical Software, 67(1), 1–48. https://doi.org/https://doi.org/10.18637/jss.v067.i01
   Web of Science ®Google Scholar
• Bjelland, I., Dahl, A. A., Haug, T. T., & Neckelmann, D. (2002). The validity of the Hospital Anxiety and Depression Scale: An updated literature review. Journal of Psychosomatic Research, 52(2), 69–77. https://doi.org/https://doi.org/10.1016/S0022-3999(01)00296-3
   PubMed Web of Science ®Google Scholar
• Blanco, J. L., Whitlock, G., Milinkovic, A., & Moyle, G. (2015). Hiv integrase inhibitors: A new era in the treatment of HIV. Expert Opinion on Pharmacotherapy, 16(9), 1313–1324. https://doi.org/https://doi.org/10.1517/14656566.2015.1044436
   PubMed Web of Science ®Google Scholar
• Cahn, P., Pozniak, A. L., Mingrone, H., Shuldyakov, A., Brites, C., Andrade-Villanueva, J. F., Richmond, G., Buendia, C. B., Fourie, J., Ramgopal, M., Hagins, D., Felizarta, F., Madruga, J., Reuter, T., Newman, T., Small, C. B., Lombaard, J., Grinsztejn, B., Dorey, D., Underwood, M., … extended SAILING Study Team. (2013). Dolutegravir versus raltegravir in antiretroviral-experienced, integrase-inhibitor-I adults with HIV: Week 48 results from the andomized, double-blind, non-inferiority SAILING study. The Lancet, 382(9893), 700–708. https://doi.org/https://doi.org/10.1016/S0140-6736(13)61221-0
   PubMed Web of Science ®Google Scholar
• Charpentier, A. (2013). Residuals from a logistic regression. Freakonometrics. An Open lab-notebook experiment. Hypotheses. Org/8210; Retrieved November 21, 2016, from. http://freakonometrics
   Google Scholar
• Clotet, B., Bellos, N., Molina, J. M., Cooper, D., Goffard, J. C., Lazzarin, A., Wöhrmann, A., Katlama, C., Wilkin, T., Haubrich, R., Cohen, C., Farthing, C., Jayaweera, D., Markowitz, M., Ruane, P., Spinosa-Guzman, S., Lefebvre, E., & POWER 1 and 2 study groups. (2007). Efficacy and safety of darunavir-ritonavir at week 48 in treatment-experienced patients with HIV-1 infection in POWER 1 and 2: A pooled subgroup analysis of data from two andomized trials. The Lancet, 369(9568), 1169–1178. https://doi.org/https://doi.org/10.1016/S0140-6736(07)60497-8
   PubMed Web of Science ®Google Scholar
• Clotet, B., Feinberg, J., Van Lunzen, J., Khuong-Josses, M. A., Antinori, A., Dumitru, I., Pokrovskiy, V., Fehr, J., Ortiz, R., Saag, M., Harris, J., Brennan, C., Fujiwara, T., Min, S., & ING114915 Study Team. (2014). Once-daily dolutegravir versus darunavir plus ritonavir in antiretroviral-I adults with HIV-1 infection (FLAMINGO): 48 week results from the andomized open-label phase 3b study. The Lancet, 383(9936), 2222–2231. https://doi.org/https://doi.org/10.1016/S0140-6736(14)60084-2
   PubMed Web of Science ®Google Scholar
• de Boer, M. G., van den Berk, G. E., van Holten, N., Oryszcyn, J. E., Dorama, W., Moha, D. A., & Brinkman, K. (2016). Intolerance of dolutegravir-containing combination antiretroviral therapy regimens in real-life clinical practice. AIDS, 30(18), 2831–2834. https://doi.org/https://doi.org/10.1097/QAD.0000000000001279
   PubMed Web of Science ®Google Scholar
• Degroote, S., Vogelaers, D. P., Vermeir, P., Mariman, A., De Rick, A., Van Der Gucht, B., Pelgrom, J., Van Wanzeele, F., Verhofstede, C., & Vandijck, D. M. (2013). Socio-economic, behavioural,(neuro) psychological and clinical determinants of HRQoL in people living with HIV in Belgium: A pilot study. Journal of the International AIDS Society, 16(1), 18643. https://doi.org/https://doi.org/10.7448/IAS.16.1.18643
   PubMed Web of Science ®Google Scholar
• Elliott, A. J., Russo, J., & Roy-Byrne, P. P. (2002). The effect of changes in depression on health related quality of life (HRQoL) in HIV infection. General Hospital Psychiatry, 24(1), 43–47. https://doi.org/https://doi.org/10.1016/s0163-8343(01)00174-8
   PubMed Web of Science ®Google Scholar
• European AIDS Clinical Society. (2020). European AIDS Clinical Society guidelines 10.1. Retrieved October 12, 2020, from https://www.eacsociety.org/files/guidelines-10.1.finalsept2020.pdf
   Google Scholar
• Hasse, B., Ledergerber, B., Furrer, H., Battegay, M., Hirschel, B., Cavassini, M., Bertisch, B., Bernasconi, E., Weber, R., & Swiss HIV Cohort Study. (2011). Morbidity and aging in HIV-infected persons: The Swiss HIV cohort study. Clinical Infectious Diseases, 53(11), 1130–1139. https://doi.org/https://doi.org/10.1093/cid/cir626
   PubMed Web of Science ®Google Scholar
• Henderson, W. A., Schlenk, E. A., Kim, K. H., Hadigan, C. M., Martino, A. C., Sereika, S. M., & Erlen, J. A. (2010). Validation of the MOS-HIV as a measure of health-related quality of life in persons living with HIV and liver disease. AIDS Care, 22(4), 483–490. https://doi.org/https://doi.org/10.1080/09540120903207292
   PubMed Web of Science ®Google Scholar
• Herrmann-Lingen, C., Buss, U., & Snaith, P. (2011). Hospital anxiety and depression scale-deutsche version (HADS-D). Huber.
   Google Scholar
• Herrmann, C., & Buss, U. (1994). Vorstellung und Validierung einer Deutschen Version der”(HAD-Skala) [Hospital anxiety and depression scale”(HAD-Skala)]. Ein Fragebogen zur Erfassung des psychischen Befindens bei Patienten mit körperlichen Beschwerden. Diagnostica.
   Google Scholar
• Hinz, A., & Brähler, E. (2011). Normative values for the hospital anxiety and depression scale (HADS) in the general German population. Journal of Psychosomatic Research, 71(2), 74–78. https://doi.org/https://doi.org/10.1016/j.jpsychores.2011.01.005
   PubMed Web of Science ®Google Scholar
• Hoffmann, C., & Llibre, J. M. (2019). Neuropsychiatric adverse events with dolutegravir and other integrase strand transfer inhibitors. AIDS Reviews, 21(1), 4–10. https://doi.org/https://doi.org/10.24875/AIDSRev.19000023
   PubMed Web of Science ®Google Scholar
• Hoffmann, C., Welz, T., Sabranski, M., Kolb, M., Wolf, E., Stellbrink, H. J., & Wyen, C. (2017). Higher rates of neuropsychiatric adverse events leading to dolutegravir discontinuation in women and older patients. HIV Medicine, 18(1), 56–63. https://doi.org/https://doi.org/10.1111/hiv.12468
   PubMed Web of Science ®Google Scholar
• Hsu, R., Fusco, J., Henegar, C., Mounzer, K., Wohlfeiler, M., Vannappagari, V., Aboud, M., Curtis, L., & Fusco, G. (2018). Psychiatric outcomes observed in patients living with HIV using six common core antiretrovirals in the observational pharmaco-epidemiology research and analysis database. Therapeutic Advances in Drug Safety, 9(12), 675–686. https://doi.org/https://doi.org/10.1177/2042098618798350
   PubMed Web of Science ®Google Scholar
• Keeshin, S. W., & Feinberg, J. (2015). Evaluation of dolutegravir safety for the treatment of HIV-1. Expert Opinion on Drug Safety, 14(1), 141–147. https://doi.org/https://doi.org/10.1517/14740338.2015.973845
   PubMed Web of Science ®Google Scholar
• Kemmler, G., Schmied, B., Shetty-Lee, A., Zangerle, R., Hinterhuber, H., Schüssler, G., & Mumelter, B. (2003). Quality of life of HIV-infected patients: Psychometric properties and validation of the German version of the MQOL-HIV. Quality of Life Research, 12(8), 1037–1050. https://doi.org/https://doi.org/10.1023/A:1026114004548
   PubMed Web of Science ®Google Scholar
• Kheloufi, F., Allemand, J., Mokhtari, S., & Default, A. (2015). Psychiatric disorders after starting dolutegravir: Report of four cases. AIDS, 29(13), 1723–1725. https://doi.org/https://doi.org/10.1097/QAD.0000000000000789
   PubMed Web of Science ®Google Scholar
• Lazarus, J. V., Safreed-Harmon, K., Barton, S. E., Costagliola, D., Dedes, N., del Amo Valero, J., Gatell, J. M., Baptista-Leite, R., Mendão, L., & Porter, K. (2016). Beyond viral suppression of HIV – the new quality of life frontier. BMC Medicine, 14(1), 1–5. https://doi.org/https://doi.org/10.1186/s12916-016-0640-4
   PubMed Web of Science ®Google Scholar
• Lüdecke, D. (2018a). Ggeffects: Tidy data frames of marginal effects from regression models. Journal of Open Source Software, 3(26), 772. https://doi.org/https://doi.org/10.21105/joss.00772
   Google Scholar
• Lüdecke, D. (2018b). sjPlot: Data Visualization for Statistics in Social Science. R package version, 2 (1). Retrieved September 22, 2020, from https://cran.r-project.org/web/packages/sjPlot/index.html
   Google Scholar
• Mellgren, Å, Eriksson, L. E., Reinius, M., Marrone, G., & Svedhem, V. (2020). Longitudinal trends and determinants of patient-reported side effects on ART-a Swedish national registry study. PLoS ONE, 15(12), e0242710. https://doi.org/https://doi.org/10.1371/journal.pone.0242710
   PubMed Web of Science ®Google Scholar
• Nash, J. C., & Varadhan, R. (2011). Unifying optimization algorithms to aid software system users: Optimx for R. Journal of Statistical Software, 43(9), 1–14. https://doi.org/http://doi.org/10.18637/jss.v043.i09
   PubMed Web of Science ®Google Scholar
• Obel, N., Omland, L. H., Kronborg, G., Larsen, C. S., Pedersen, C., Pedersen, G., Sørensen, H. T., & Gerstoft, J. (2011). Impact of non-HIV and HIV risk factors on survival in HIV-infected patients on HAART: A population-based nationwide cohort study. PLoS ONE, 6(7), e22698. https://doi.org/https://doi.org/10.1371/journal.pone.0022698
   PubMed Web of Science ®Google Scholar
• Oglesby, A., Angelis, K., Punekar, Y., Chounta, V., Antela, A., Matthews, J., Kahl, L., Gartland, M., Wynne, B., Murray, M., & Van Wyk, J. A. (2019). 2484. Patient reported outcomes after switching to a 2-drug regimen of dolutegravir+rilpivirine: Week 148 results from the sword-1 and sword-2 studies. Open Forum Infectious Diseases, 6(Suppl. 2), S861–S861. https://doi.org/https://doi.org/10.1093/ofid/ofz360.2162
   Google Scholar
• Patel, D. A., Snedecor, S. J., Tang, W. Y., Sudharshan, L., Lim, J. W., Cuffe, R., Pulgar, S., Gilchrist, K. A., Camejo, R. R., Stephens, J., & Nichols, G. (2014). 48-week efficacy and safety of dolutegravir relative to commonly used third agents in treatment-I HIV-1–infected patients: A systematic review and network meta-analysis. PLoS ONE, 9(9), e105653. https://doi.org/https://doi.org/10.1371/journal.pone.0105653
   PubMed Web of Science ®Google Scholar
• Petermann, F. (2015). Hospital anxiety and depression scale, deutsche version (HADS-D). Zeitschrift für Psychiatrie Psychologie und Psychotherapie.
   Google Scholar
• Raffi, F., Jaeger, H., Quiros-Roldan, E., Albrecht, H., Belonosova, E., Gatell, J. M., Baril, J. G., Domingo, P., Brennan, C., Almond, S., Min, S., & extended SPRING-2 Study Group. (2013). Once-daily dolutegravir versus twice-daily raltegravir in antiretroviral-I adults with HIV-1 infection (SPRING-2 study): 96 week results from a randomized, double-blind, non-inferiority trial. The Lancet Infectious Diseases, 13(11), 927–935. https://doi.org/https://doi.org/10.1016/S1473-3099(13)70257-3
   PubMed Web of Science ®Google Scholar
• R Core Team. (2019). R: A language and environment for statistical computing. Vienna, Austria.
   Google Scholar
• Rief, W., Hofmann, S. G., & Nestoriuc, Y. (2008). The power of expectation - understanding the placebo and nocebo phenomenon. Social and Personality Psychology Compass, 2(4), 1624–1637. https://doi.org/https://doi.org/10.1111/j.1751-9004.2008.00121.x
   Google Scholar
• Ronel, J., Dinkel, A., Wolf, E., Marten-Mittag, B., Mueck, B., Mayr, C., Hoffmann, C., Karwat, M., Schewe, K., Baumgarten, A., & Jaeger, H. (2018). Anxiety, depression, and health-related quality of life in aging people living with HIV compared to diabetes patients and patients with minor health conditions: A longitudinal study. Psychology, Health and Medicine, 23(7), 823–830. https://doi.org/https://doi.org/10.1080/13548506.2018.1437276
   PubMed Web of Science ®Google Scholar
• Scheper, H., Van Holten, N., Hovens, J., & De Boer, M. (2018). Severe depression as a neuropsychiatric side effect induced by dolutegravir. HIV Medicine, 19(4), e58–e59. https://doi.org/https://doi.org/10.1111/hiv.12538
   PubMed Web of Science ®Google Scholar
• Schober, P., & Vetter, T. R. (2018). Repeated measures designs and analysis of longitudinal data: If at first you do not succeed—try, try again. Anesthesia and Analgesia, 127(2), 569–575. https://doi.org/https://doi.org/10.1213/ANE.0000000000003511
   PubMed Web of Science ®Google Scholar
• Smit, M., Brinkman, K., Geerlings, S., Smit, C., Thyagarajan, K., van Sighem, Av, de Wolf, F., Hallett, T. B., & ATHENA observational cohort. (2015). Future challenges for clinical care of an ageing population infected with HIV: A modelling study. The Lancet Infectious Diseases, 15(7), 810–818. https://doi.org/https://doi.org/10.1016/S1473-3099(15)00056-0
   PubMed Web of Science ®Google Scholar
• Song, I., Min, S. S., Borland, J., Lou, Y., Chen, S., Patel, P., Ishibashi, T., & Piscitelli, S. C. (2011). The effect of lopinavir/ritonavir and darunavir/ritonavir on the HIV integrase inhibitor S/GSK1349572 in healthy participants. The Journal of Clinical Pharmacology, 51(2), 237–242. https://doi.org/https://doi.org/10.1177/0091270010371113
   PubMed Web of Science ®Google Scholar
• Spinner, C. D., Kümmerle, T., Schneider, J., Cordes, C., Heiken, H., Stellbrink, H., Krznaric, I., Scholten, S., Jensen, B., Wyen, C., Viehweger, M., Lehmann, C., Sprinzl, M., Stoehr, A., Bickel, M., Jessen, H., Obst, W., Spornraft-Ragaller, P., Khaykin, P., & Boesecke, C. (2020). Efficacy and safety of switching to dolutegravir with boosted darunavir in virologically suppressed adults with HIV-1: A randomized, open-label, multicenter, phase 3, non-inferiority trial: The DUALIS study. Open Forum Infectious Diseases, 7(9). https://doi.org/https://doi.org/10.1093/ofid/ofaa356
   Google Scholar
• Stellbrink, H. J., Reynes, J., Lazzarin, A., Voronin, E., Pulido, F., Felizarta, F., Almond, S., St Clair, M., Flack, N., Min, S., & SPRING-1 Team. (2013). Dolutegravir in antiretroviral-I adults with HIV-1: 96-week results from a randomized dose-ranging study. AIDS (London, England), 27(11), 1771–1778. https://doi.org/https://doi.org/10.1097/QAD.0b013e3283612419
   PubMed Web of Science ®Google Scholar
• Todd, S. E. J., Rafferty, P., Walker, E., Hunter, M., Dinsmore, W. W., Donnelly, C. M., McCarty, E. J., Quah, S. P., & Emerson, C. R. (2017). Early clinical experience of dolutegravir in an HIV cohort in a larger teaching hospital. International Journal of STD and AIDS, 28(11), 1074–1081. https://doi.org/https://doi.org/10.1177/0956462416688127
   PubMed Web of Science ®Google Scholar
• Van den Berk, G., Oryszczyn, J., Blok, W., Van der Meche, N., Regez, R., Moha, D., & Brinkman, K. (2016). Unexpectedly high rate of intolerance for dolutegravir in a real-life setting. (Ed.), (Eds.). Retroviruses and Opportunistic Infections.
   Google Scholar
• Walmsley, S. L., Antela, A., Clumeck, N., Duiculescu, D., Eberhard, A., Gutiérrez, F., Hocqueloux, L., Maggiolo, F., Sandkovsky, U., Granier, C., Pappa, K., Wynne, B., Min, S., Nichols, G., & Investigators SINGLE. (2013). Dolutegravir plus Abacavir–lamivudine for the treatment of HIV-1 infection. New England Journal of Medicine, 369(19), 1807–1818. https://doi.org/https://doi.org/10.1056/NEJMoa1215541
   PubMed Web of Science ®Google Scholar
• Wu, A. W., Revicki, D. A., Jacobson, D., & Malitz, F. E. (1997). Evidence for reliability, validity, and usefulness of the Medical Outcomes Study HIV Health Survey (MOS-HIV). Quality of Life Research, 6(6), 481–493. https://doi.org/https://doi.org/10.1023/a:1018451930750
   PubMed Web of Science ®Google Scholar
• Zander, K., Palitzsch, M., Kirchberger, I., Poppinger, J., & Jägel-Guedes, E. (1994). HIV-Infektion und gesundheitsbezogene Lebensqualität: psychometrische Prüfund der deutschsprachigen Version Des “MOS-HIV"-Fragebogens zur Therapieerfolgskontrolle. AIDS-Forschung, 9(5), 241–252.
   Google Scholar
• Zigmond, A. S., & Snaith, R. P. (1983). The Hospital anxiety and depression scale. Acta Psychiatrica Scandinavica, 67(6), 361–370. https://doi.org/https://doi.org/10.1111/j.1600-0447.1983.tb09716.x
   PubMed Web of Science ®Google Scholar